Picankibart Biosimilar - Research Grade

Human

IL23A

>1mg/ml

IgG1 - kappa

CHO Cells

Guselkumab Biosimilar - Research Grade (ICH5064), Risankizumab Biosimilar - Research Grade (ICH5210), Tildrakizumab Biosimilar - Research Grade (ICH5303), Brazikumab Biosimilar - Research Grade (ICH5413), Mirikizumab Biosimilar - Research Grade (ICH5683)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NPF7

51561

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of picankibart, an anti-IL-23 antibody built around the human IL-23 p19 subunit (IL23A, UniProt Q9NPF7). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. The analog reproduces the binding specificity of the originator format (human IgG1, kappa) so investigators can interrogate IL-23-dependent signaling in controlled settings. Typical research applications include use as a specificity or isotype-matched benchmarking reagent, a binding and neutralization tool against recombinant human IL-23, a positive control in ligand-capture and receptor-blockade assays, and a starting reagent for ADCC/ADC and biosimilarity development workflows. It is offered as a low-endotoxin, research-grade preparation (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support assay development, in-vitro pharmacology, and preclinical characterization. Lot-to-lot consistency and defined formulation make it suitable as a reference standard across repeated experiments. IL23A encodes the p19 subunit of interleukin-23, a heterodimeric cytokine formed by covalent pairing of p19 with the p40 subunit (IL12B) that is shared with IL-12. p19 confers IL-23-specific identity, distinguishing it from IL-12 (p35/p40). IL-23 is produced largely by activated dendritic cells and macrophages and signals through a receptor complex of IL23R and IL12RB1, engaging JAK2/TYK2 and predominantly STAT3. Its central role is to sustain and expand pathogenic T helper 17 (Th17) cells and to drive production of IL-17A, IL-17F, IL-22, and GM-CSF, while also acting on innate lymphoid cells and gamma-delta T cells. This IL-23/Th17 axis is a well-validated driver of chronic inflammation in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Selectively blocking p19 neutralizes IL-23 while sparing IL-12-dependent Th1 responses.

IL-23 subunit alpha, Interleukin-23 subunit p19, IL-23p19, Interleukin-23 subunit alpha, SGRF

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Picankibart (anti-IL23A) Biosimilar

Q: Is the Picankibart biosimilar available in bulk or gram quantities?

A: Yes — the Picankibart biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Picankibart suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Picankibart biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Picankibart that binds IL23A; for research use only (RUO).